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Abstract
Type 1 diabetes mellitus is caused by the autoimmune 
destruction of β cells within the islets. In recent years, 
innate immunity has been proposed to play a key role 
in this process. High-mobility group box 1 (HMGB1), an 
inflammatory trigger in a number of autoimmune dis-
eases, activates proinflammatory responses follow-
ing its release from necrotic cells. Our aim was to de-
termine the significance of HMGB1 in the natural his-
tory of diabetes in non-obese diabetic (NOD) mice. We 
observed that the rate of HMGB1 expression in the cy-
toplasm of islets was much greater in diabetic mice 
compared with non-diabetic mice. The majority of cells 
positively stained for toll-like receptor 4 (TLR4) were β 
cells; few α cells were stained for TLR4. Thus, we exam-
ined the effects of anti-TLR4 antibodies on HMGB1 cell 
surface binding, which confirmed that HMGB1 inter-
acts with TLR4 in isolated islets. Expression changes 
in HMGB1 and TLR4 were detected throughout the 
course of diabetes. Our findings indicate that TLR4 is 
the main receptor on β cells and that HMGB1 may signal 
via TLR4 to selectively damage β cells rather than α 
cells  during  the  development  of  type  1  diabetes 
mellitus.
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Introduction
Type 1 diabetes mellitus (T1DM), also known as 
insulin-dependent diabetes mellitus or juvenile 
diabetes, is generally believed to be caused by an 
interaction between the immune system and an 
intricate network of environmental and genetic 
factors (Pino et al., 2010). The key feature of T1DM 
is cell-mediated destruction of insulin-secreting β 
cells in the pancreatic islets (Giarratana et al., 2004).
    HMGB1 was initially identified nearly 30 yr ago as 
a nuclear protein that is important for transcriptional 
regulation. HMGB1 causes DNA bending and 
facilitates the binding of several regulatory protein 
complexes to DNA (Zhang et al., 1999; Lotze and 
Tracey, 2005; Li et al., 2010). In addition to its role in 
transcriptional regulation, HMGB1 has been shown to 
activate proinflammatory responses following its 
release by necrotic cells into the extracellular 
environment (Wang et al., 2010). HMGB1 is also 
implicated in the pathogenesis of a number of 
diseases associated with inflammation and tissue 
injury (Wang et al., 2010). Recently, many studies 
have suggested that HMGB1 acts as an 
inflammatory trigger in autoimmune diseases such 
as rheumatoid arthritis and systemic lupus 
erythematosus (SLE) (Wittemann et al., 1990; 
Abdulahad et al., 2010).
    Several important receptors have been implicated 
in HMGB1 signaling, including members of the 
toll-like family of receptors (TLRs) and the receptor 
for advanced glycation end products (RAGE) (Klune 
et al., 2008). The TLR family is an evolutionarily 
conserved component of the innate immune system TLR4 interacts with HMGB 1 in T1DM    261
Figure 1. Hematoxylin and eosin staining of pancreatic sections demon-
strates extensive islet destruction in diabetic NOD mice (B) compared 
with 4-week-old, non-diabetic NOD mice (A). Immunohistochemical stain-
ing shows preferential localization of HMGB1 in the nuclei of islet cells in 
4-week-old non-diabetic mice (C, E). HMGB1 expression in the cytoplasm 
of the islets is much higher with the development of diabetes (D, F). The 
rate of HMGB1 expression in the cytoplasm of islets was much greater in 
diabetic mice compared with non-diabetic mice (E) **P ＜ 0.01 (n =9  
per group).
(Medzhitov, 2007). The recent discovery of TLRs 
and studies performed in animal models of the 
disease led to the hypothesis that the innate 
immune system plays a key role in triggering the 
autoimmune process (Meyers et al., 2010). RAGE, 
which specifically binds advanced glycation end 
products, is a member of the immunoglobulin 
superfamily of cell surface receptors (Song et al., 
2011). HMGB1 may signal TLRs and RAGE to 
activate nuclear factor-κB (NF-κB), which induces 
the production of proinflammatory cytokines and the 
upregulation of leukocyte adhesion molecules, 
thereby promoting injury and inflammation (Van 
Beijnum et al., 2008; Nogueira-Machado et al., 2011).
    It is well known that α cells are not affected during 
the development of diabetes, whereas β cells 
undergo extensive destruction, even though α cells 
form a ring and provide a physical barrier around the 
β cells. In the present study, the distribution of 
HMGB1 in the pancreas was examined by 
immunohistochemical staining, which demonstrated 
that the the rate of HMGB1 expression in the 
cytoplasm of islets was much greater in diabetic 
mice compared with non-diabetic mice. The non-obese 
diabetic (NOD) mouse develops a spontaneous 
form of autoimmune diabetes that mimics many 
features of the human disease and typically 
develops at 12 to 14 weeks of age (Anderson and 
Bluestone, 2005). We tested our hypothesis that 
distinct HMGB1 receptors are distributed on 
different pancreatic cell types in NOD mice. Thus, 
we examined the effects of anti-TLR2, anti-TLR4, 
anti-TLR9 and anti-RAGE antibodies on HMGB1 
cell surface binding, which confirmed that HMGB1 
interacts with TLR4 in isolated islets. These changes 
in HMGB1 and TLR4 were detected throughout the 
course of diabetes, being significantly upregulated 
in the early stages of diabetes and then slowly 
decreasing over time. Our data provide strong 
evidence that TLR4 is the main receptor on β cells 
and that HMGB1, which is passively released from 
damaged islet cells, acts through the TLR4 signaling 
pathway to selectively damage β cells rather than α 
cells during the development of autoimmune 
diabetes.
Results
HMGB1 is associated with islet destruction
Because it has been reported that HMGB1 can be 
passively released from damaged cells (Abdulahad 
et al., 2010) or necrotized tissues (Lin et al., 2011a, 
2011b), we examined whether it is also released 
from damaged islet cells in T1DM using NOD mice. 
Histological and morphological assessment of 
pancreatic sections stained with hematoxylin and 
eosin indicated extensive islet destruction (Figure 
1B) in diabetic NOD mice compared with 4-week-old 
non-diabetic mice (Figure 1A). We also examined 
the expression and cellular distribution of HMGB1 in 
the specimens of NOD pancreatic tissues by 
immunohistochemical staining. HMGB1 was mainly 
localized in the nuclei of islet cells in 4-week-old 
non-diabetic NOD mice (Figure 1C). However, 
HMGB1 increased in the cytoplasm of islets with the 
progression of diabetes (Figure 1D). The rate of 
HMGB1 expression in the cytoplasm of islets was 
much greater in diabetic mice compared with non- 
diabetic mice (P ＜0.01) (Figure 1E). Taken together, 262    Exp. Mol. Med. Vol. 44(4), 260-267, 2012
Figure 2. Expression of HMGB1 re-
ceptors (TLR2, TLR4, TLR9 and 
RAGE) and insulin in pancreatic is-
lets of 4-week-old non-diabetic NOD 
mice. (A, E, I, M) Insulin im-
munostaining (red) of β cells. (B, F, 
J, N) TLR2, TLR4, TLR9 and RAGE 
immunostaining (green). (C, G, K, 
O) DAPI nuclear staining (blue). 
Pancreatic islets from 4-week-old 
non-diabetic NOD mice show little or 
no expression of TLR2 (B), TLR9 (J) 
or RAGE (N). In contrast, TLR4 is 
highly expressed on the islets (green) 
in 4-week-old non-diabetic NOD 
mice (F).Co-localization (yellow) of 
TLR4 and insulin (H) suggested that 
TLR4 is mainly expressed in β cells.
our data suggest that HMGB1 may be passively 
released from damaged islet cells or inflamed islet 
cells during autoimmunity.
Expression of HMGB1 receptors on the pancreatic 
islets of NOD mice
The expression and cellular distributions of HMGB1 
receptors, including TLR2, TLR4, TLR9 and RAGE, 
in the pancreatic islets of NOD mice were examined 
by immunofluorescence and visualized by confocal 
microscopy. Little or no expression of TLR2, TLR9 
or RAGE was observed in the pancreatic islets of 
4-week-old, non-diabetic NOD mice (Figures 2B 
and 2J and 2N). In contrast, TLR4 was mainly 
localized in the islets and indicated increased 
expression in 4-week-old non-diabetic NOD mice 
(Figure 2F).
    Next, we investigated which of the pancreatic cell 
types were positive for TLR4 receptors. We performed 
double-labeling for islet α cells and β cells separately 
with TLR4 in 4-week-old non-diabetic NOD mice. 
TLR4 was mainly distributed in the cytoplasm. 
Furthermore, the cells expressing TLR4 were 
insulin-positive cells (i.e., β cells), which comprise the 
majority of cells in the islet (Figures 2E-2H). The 
glucagon-positive cells (α cells) formed a ring 
around the islet; however, relatively few α cells 
expressed TLR4 (Figure 3).
HMGB1 interacts with TLR4 in isolated islet cells
To further study the interactions between HMGB1 
and its corresponding receptors, we examined the 
effects of anti-TLR2, anti-TLR4, anti-TLR9 and 
anti-RAGE antibodies on HMGB1 cell surface 
binding in islets using confocal microscopy. Islets 
were isolated from 4-week-old non-diabetic NOD 
mice and purified by handpicking. The dispersed 
islet cells were then cultured in a standard medium. 
Cell surface binding of N-Hydroxysuccinimide 
(NHS)-fluorescein-HMGB1 was observed in islet 
cells incubated with NHS-fluorescein-HMGB1 for 6 
h at 4
oC, and the staining formed an annular pattern 
(Figure 4A). Pretreatment with anti-TLR2, anti-TLR9, 
anti-RAGE or IgG did not significantly influence TLR4 interacts with HMGB 1 in T1DM    263
Figure 3. TLR4 is not expressed in α cells. Islets from 4-week-old non-diabetic NOD mice were double-labeled with TLR4 and glucagon. (A) Glucagon 
immunostaining (red). (B) TLR4 receptor immunostaining (green). (C) DAPI nuclear staining (blue). (D) Co-localization of TLR4 and glucagon indicate 
sparse expression of TLR4 in α cells.
Figure 4. Effects of TLR antibodies on cell surface binding of HMGB1. Islets were isolated from 4-week-old non-diabetic NOD mice, plated in six-well 
plates and used at 70% confluence. (A) Incubation of islets with NHS-fluorescein-HMGB1 for 6 h at 4
oC resulted in an annular staining pattern. (B-G) Cells 
were also preincubated with 25 μg/mL of anti-TLR2 (B), TLR9 (C), RAGE (D), IgG (E), TLR4 (F) or unlabeled HMGB1 (G) for 30 min at 4
oC in Opti-MEM I 
medium, followed by 5 μg/mL NHS-fluorescein-labeled HMGB1 for 6 h at 4
oC. Cells were then washed three times with PBS (pH 7.2) and fixed for 20 min 
at room temperature in 2% paraformaldehyde-PBS. After fixing, fluorescence was recorded with a confocal microscope.
HMGB1 cell surface binding (Figures 4B-4E). 
However, anti-TLR4 antibodies (Figure 4F) or 
unlabeled HMGB1 (Figure 4G) decreased HMGB1 
cell surface binding, visualized by a reduction in 
cell-associated fluorescence intensity compared 
with IgG-treated controls. These results indicate that 
HMGB1 physically interacts with TLR4 in islet cells.
HMGB1 and TLR4 protein expression in the pancreas 
of NOD mice
Pancreatic HMGB1 and TLR4 protein expression 
was evaluated by western blotting at various times 
in the natural history of diabetes in NOD mice 
(Figure 5). Pancreatic expression of both HMGB1 
and TLR4 was low in young NOD mice (4-6 weeks 
of age). In contrast, the pancreatic expression of 
HMGB1 and TLR4 was significantly upregulated in 
the early stage of diabetes (10-14 weeks of age) (P
＜0.01). To our surprise, in older diabetic mice 
(28-32 weeks of age), the protein expression of 
HMGB1 and TLR4 was markedly downregulated (P
＜0.01).
Changes in pancreatic HMGB1 and TLR4 mRNA 
expression during the development of diabetes in 
NOD mice
We assessed pancreatic HMGB1 and TLR4 mRNA 
expression every 3-5 weeks during the development 
of diabetes in NOD mice (Figure 6). This analysis 
showed no marked changes in HMGB1 mRNA 
expression in the first 8 weeks of life of NOD mice. 
However, HMGB1 mRNA expression was significantly 
increased at 10 weeks of age, which was followed 
by slow reduction in expression over time to reach 
levels similar to that at 8 weeks of age.
    The NOD mice displayed much homogeneity in 
the expression of TLR4 mRNA during the development 
of diabetes. At 6 weeks of age, there was a distinct 
increase in TLR4 mRNA expression compared with 
that at 4 weeks of age. This increase was transient 264    Exp. Mol. Med. Vol. 44(4), 260-267, 2012
Figure  5. Western blotting analysis of HMGB1 and TLR-4 protein 
expression. Pancreatic expression of HMGB1 and TLR4 was low in 
non-diabetic NOD mice (4-6 weeks of age). In the early stage of diabetes 
(10-14 weeks of age), the expression of HMGB1 and TLR4 protein was 
significantly upregulated. In contrast, the expression of HMGB1 and 
TLR4 was decreased in mice with established diabetes (28-32 weeks of 
age). The data are from three independent experiments. **P ＜ 0.01 ver-
sus control and late-stage normal mice.
Figure 6. Pancreatic mRNA expression of HMGB1 and TLR-4 mRNA. 
Pancreatic tissue was obtained from NOD mice (8 mice per time) every 
3-5 weeks from 4 to 32 weeks of age and subjected to qRT-PCR. Values 
are means ± standard error of the mean. The data are from three in-
dependent experiments. *P ＜ 0.05 (HMGB1) for 8 versus 10 weeks of 
age, 10 versus 12 weeks of age, 12 versus 16 weeks of age and 20 ver-
sus 26 weeks of age (Wilcoxon’s signed rank test). **P ＜ 0.05 (TLR4) 
for 4 versus 6 weeks of age, 6 versus 8 weeks of age, 8 versus 10 weeks 
of age, 12 versus 16 weeks of age, 16 versus 20 weeks of age and 26 
versus 32 weeks of age (Wilcoxon’s signed rank test).
and followed by a significant increase in TLR4 
mRNA expression between 8 and 10 weeks of age, 
followed by a significant reduction in the values in 
later weeks.
Discussion
HMGB1 originated more than 500 million yr ago 
before the split between the animal and plant 
kingdoms (Han et al., 2008). Therefore, it is one of 
the most evolutionarily conserved proteins in the 
eukaryotic kingdom, shareing 99% amino acid 
identity between rodents and humans (Han et al., 
2008). HMGB1 can be either passively released by 
injured or necrotic cells or actively secreted by 
macrophages (Lin et al., 2011a). The release of 
HMGB1 into the extracellular environment, where it 
can function as an endogenous danger signal or 
‘alarmin’ to promote inflammation, is implicated in 
several diseases such as sepsis and acute lung 
injury (Wang et al., 2010).
    HMGB1 exerts pleiotropic effects by binding to 
several members of the toll-like family, including 
TLR2, TLR4, TLR9 and RAGE, and thus promotes 
inflammatory processes (Klune et al., 2008; Gdynia 
et al., 2010). TLRs are type 1 transmembrane re-
ceptors and recognize distinct pathogen-associated 
molecular patterns (PAMPs) through their leucine- 
rich repeats in the extracytoplasmic domain 
(Miranda-Hernandez et al., 2011). TLRs can also 
recognize endogenous material during cellular in-
jury (Johnson et al., 2003). The TLR family plays an 
essential role in innate and adaptive immune recog-
nition in mammals. For example, TLR4 recognizes 
the Gram-negative product lipopolysaccharide and 
participates in the recognition of several endogen-
ous ligands, including heat shock proteins, whereas 
TLR2 recognizes various fungal, Gram- positive and 
mycobacterial components (Yu et al., 2006). TLR9 
recognizes bacterial CpG DNA sequences, and 
HMGB1 is involved in TLR9 activation, resulting in 
the maturation of immune cells and cytokine secre-
tion (Klune et al., 2008; Miranda-Hernandez et al., 
2011). Moreover, HMGB1-dependent activation of 
RAGE leads to activation of the NF-κB pathway, as 
well as signal transduction through ERK and p38, to 
promote cytokine production and cell survival (Lotze 
and Tracey, 2005).
    T1DM is an autoimmune disease in which dis-
ordered innate immune response signaling is asso-
ciated with disease progression. Current evidence sug-
gests that abnormalities within the innate immune 
system play key roles in the pathogenesis of T1DM. 
In some people with T1DM, viral infection can lead 
to NK-dominant insulitis, β cell dysfunction and 
eventually to overt hyperglycemia and diabetes 
(Grieco et al., 2011). The expression of TLR2 and 
TLR4, along with their downstream targets, was in-
creased in monocytes obtained from patients with 
T1DM (Pino et al., 2010). Using a streptozotocin- in-
duced diabetic C57BL/6 mouse model, Devaraj et 
al. found that genetic deficiency of TLR4 significantly 
reduced MyD88 and IRAK-1 protein phosphorylation 
and NF-κB activity, and attenuated the proin-TLR4 interacts with HMGB 1 in T1DM    265
flammatory state of T1DM (Devaraj et al., 2011).
        The purpose of this study was to examine 
whether HMGB1 participates in the pathogenesis of 
T1DM and to identify the receptor involved in 
HMGB1-mediated activation of inflammatory signaling 
in NOD mice. First, we observed that the rate of 
HMGB1 expression in the cytoplasm of islets was 
much greater in diabetic mice compared with 
non-diabetic mice, which may be associated with 
islet destruction or insulitis. We proceeded to the 
expression of HMGB1 receptors (TLR2, TLR4, 
TLR9 and RAGE) on different pancreatic islet cells 
from non-diabetic NOD mice. We found that the 
majority of cells positively stained for TLR4 were β 
cells, and these comprised the majority of cells 
within the islets. The expression of both HMGB1 
and TLR4 was upregulated in the early stage of 
diabetes (8-10 weeks of age), which may hasten the 
development of diabetes. However, the expression 
of both HMGB1 and TLR4 was significantly decreased 
in the late stage of diabetes (16-32 weeks of age) 
compared with the early stage of diabetes (8-10 
weeks of age), which may result from the destruction 
of the majority of β cells within the islets and the 
reduction in the number of corresponding receptors. 
Our current findings indicate that TLR4 on β cells 
could sense changes in HMGB1 released from necrotic 
islet cells, which may lead to a proinflammatory 
state around the islets and contribute to the initiation 
of autoimmune diabetes.
    To  our  knowledge,  this  report  is  the  first  to 
describe a relationship between HMGB1 and its 
receptors on the isolated islets of NOD mice, an 
excellent model for T1DM in humans. We determined 
the changes that occur in pancreatic HMGB1 and 
TLR4 protein and mRNA expression throughout the 
course of diabetes in NOD mice. Our observations 
suggest that TLR4 is the main receptor on β cells 
and that HMGB1 is passively released from 
damaged islet cells acts via T L R4  t o  s e l e c t i v e l y 
damage β cells rather than α cells in the early stages 
of diabetes. Consequently, TLR4 may serve as an 
early marker for β cell destruction, although studies 
of patients with T1DM are necessary to confirm this 
hypothesis. In future studies, we will examine TLR4 
expression and signaling in type 2 diabetes, which is 
also a proinflammatory condition.
Methods
Mice
All animal experiments were performed in accordance with 
the guide for the Care and Use of Laboratory Animals ap-
proved by the Institutional Ethics Board of the Zhongshan 
Hospital of Fudan University. Healthy, 4-week-old (15-17 g) 
female NOD/JSlac mice were purchased from the 
Shanghai Laboratory Animal Center, Chinese Academy of 
Sciences. All the animals were housed in the specific 
pathogen-free animal facility of Zhongshan Hospital, Fudan 
University, Shanghai. Each mouse was weighed and the 
peripheral blood glucose level was monitored (A010120; 
Bayer, Germany) weekly before the animal was killed. 
Diabetes was diagnosed when two consecutive blood glu-
cose measurements indicated values greater than 13.0 
mmol/L (Yaacob et al., 2009). 
Histological and morphological analyses
Mice pancreases were excised and fixed overnight in 4% 
paraformaldehyde at 4
oC. Fixed tissues were processed 
for paraffin embedding and serial 5 μm thick sections were 
prepared and stained with hematoxylin and eosin 
(Beyotime Institute of Biology, Suzhou, China) to assess 
pancreatic islets histology and morphology in the ex-
perimental animals. Histology and morphology of islets 
were scored with a Carl-Zeiss microscopy Axiovert 200 
(Carl-Zeiss, Jena, Germany).
Immunofluorescence and confocal analysis
The pancreases of NOD mice were embedded with OCT 
Compound (Sakura Finetechnical Co., Ltd., Tokyo, Japan). 
Consecutive cryostat sections, 10 μm, were cut and 
air-dried at room temperature. The sections were first in-
cubated overnight with primary antibody at 4
oC. Guinea 
pigs anti-mouse-insulin antibody (Invitrogen, Carlsbad, 
CA), goat anti-mouse-glucagon antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA), rabbit anti-mouse-HMGB1 
antibody (Abcam, Cambridge, UK), mouse monoclonal 
T2.5 to TLR2 (Abcam), rabbit anti-mouse-TLR4 antibody 
(Abcam), mouse monoclonal 26C593 to TLR9 (Abcam) 
and rabbit anti-mouse-RAGE antibody (Millipore, Billerica, 
MA) were the primary antibodies. The sections were wash-
ed three times with PBS and incubated for 2 h at room 
temperature with Cy3 conjugated donkey anti-GP secon-
dary antibody (Millipore), Alexa Fluor 555 donkey anti-goat 
secondary antibody (Invitrogen), Alexa Fluor 488 goat an-
ti-rabbit secondary antibody (Invitrogen), Alexa Fluor 555 
goat anti-rabbit secondary antibody (Invitrogen) and Alexa 
Fluor 488 donkey anti-mouse secondary antibody (Invitrogen). 
The nuclear regions were stained by DAPI (Sigma-Aldrich) 
counterstaining. Finally, the sections mounted by glycer-
ol/PBS (1:1). Isotype-matched antibodies and PBS were 
used as controls for stained sections. The samples were 
visualized on a Leica TCS SP5 confocal microscope 
(Leica, Mannheim, Germany). 
Separation and culture of islet cells
The pancreas was distended via bile duct puncture and 
retrograde injection of 1.5-2 ml of ice-cold collagenase type 
V (Sigma-Aldrich, St. Louis, MO). The gland was removed 
and placed into the D-Hank’s balanced salt solution con-
taining collagenase type V. The pancreas was digested at 
37
oC under continuous shaking. The digest was washed 
three times with RPMI 1640 (Gibco, Incorporated, Invitrogen, 
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purification as described (Sutton et al., 1986). The sepa-
rated islets were further purified by handpicking using ca-
pillary pipettes (BD, Franklin Lakes, NJ) and were identi-
fied by selectively staining crimson red with Dithizone 
(DTZ) for the purity of the islets. Then, the dispersed islet 
cells were cultured in the standard medium, RPMI 1640 
(Gibco) supplemented with 10% fetal bovine serum (FBS) 
(Gibco), 20 mmol/L hydroxyethyl piperazine ethanesulfonic 
acid (HEPES) (Sigma-Aldrich), and 10 mmol/L niacinamide 
(Sigma-Aldrich) at 37
oC in 95% O2/5% CO2 and saturated 
humidity. 
NHS-fluorescein labeling of HMGB1 and cellular 
immunofluorescence
HMGB1 (eBioscience, San Diego, CA) protein was labeled 
with NHS-fluorescein (Pierce Biotechnology, Rockford, Il) 
according to the manufacturer’s instructions. Islet cells 
were isolated from 4-week-old non-diabetic NOD mice and 
plated in six-well plates (Corning Inc., Corning, NY). Cells 
were used at 70% confluence. Cells were preincubated 
with anti-TLR2, -TLR4, -TLR9 or -RAGE antibodies (25 μg/mL) 
for 30 min at 4
oC in Opti-MEM I medium (Invitrogen). Cells 
were then treated with 5 μg/mL NHS-fluorescein-labeled 
HMGB1 and incubated for an additional 6 h at 4
oC (Yu et 
al., 2006). Cells were then washed three times with PBS 
(pH 7.2) and fixed for 20 min at room temperature in 2% 
paraformaldehyde-PBS. After fixing, the fluorescence was 
recorded with a Leica TCS SP2 upright confocal micro-
scope (Leica, Mannheim, Germany).
Western blotting analysis
Fifty micrograms of protein isolated from the pancreas of 
NOD mice was electrophoresed in 10% of sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis gels and trans-
ferred onto polyvinylidene difluoride membranes (Millipore). 
After blocking with 5% non-fat milk, the membranes were 
incubated with primary antibodies recognizing HMGB1 
(Abcam) and TLR4 (Abcam) overnight at 4
oC. Strips were 
then incubated with horseradish peroxidase (HRP)-conju-
gated goat anti-mouse and goat anti-rabbit secondary anti-
bodies (Jackson ImmunoResearch Laboratories, West 
Grove, PA) for 1 h at room temperature. Proteins were vi-
sualized using enhanced chemiluminescence (ECL) west-
ern blotting detection reagents (Pierce) and quantified using 
a Bio-Rad Fluor-S Multi-Imager (Typhoon 9400, Amersham, 
Sweden).
qRT-PCR analysis
Total RNA (1 μg from whole pancreas) was extracted and 
purified using TRIzol (Invitrogen) according to the manu-
facturer’s instructions. Equal amounts of RNA were then 
reverse-transcribed into cDNA using a PrimeScript
Ⓡ RT re-
agent Kit (Takara Biotec, Kyoto, Japan). Quantitative real- 
time PCR was performed using the Mastercycler
Ⓡ ep real-
plex real-time PCR system (Eppendorf, Hamburg, Germany) 
with SYBR green PCR master mix (Takara Biotec). The pri-
mers used for PCR were as follows: HMGB1, forward: 
GAGAGATGTGGAACAACACTGC, reverse: AGCTCTGT-
AGGCAGCAATATCC, 104 bp; TLR-4, forward: TTTCACC-
TCTGCCTTCACTACA, reverse: AGATACACCAACGGCT-
CTGAAT, 139 bp; β-actin, forward: GTCCCTCACCCTCC-
CAAAAG, reverse: GCTGCCTCAACACCTCAACCC, 266 
bp. Cycling conditions were as follows: initial activation at 
95
oC for 30 s; following 40 cycles for 5 s at 95
oC and for 30 
s at 60
oC. The levels of target mRNA on cells were ana-
lyzed using the 2
-ΔΔCt method.
Statistical analysis
Statistically significant differences between groups were 
assessed using parametric tests or non-parametric tests as 
appropriate. Values are presented as means ± standard 
error of the mean. Statistical analysis was performed using 
SPSS 17.0 software. Values of P ＜0.05 were considered 
statistically significant.
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